Oncology
12 drugs are in development for Breast Cancer.
- Companies
- 12
- Clinical trials
- 355
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Breast Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| nerlynx | PUMA BIOTECHNOLOGY, INC. (PBYI) |
Phase 3(3)
Phase 2(1)
| Drug | Company |
|---|---|
| ae37 | GENEREX BIOTECHNOLOGY CORP (GNBT) |
Phase 1(6)
Preclinical(1)
| Drug | Company |
|---|---|
| xp-105 | XYNOMIC PHARMACEUTICALS HOLDINGS, INC. (BCACU) |
About this indication
Breast Cancer context
Oncology·MeSH: Breast Neoplasms (D001943)
Narrower concept of MeSH descriptor Breast Neoplasms
Prevalence
287.0 / 100K
Incidence
128.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Breast Cancer?
BioSniper tracks 12 drugs in development for Breast Cancer across 12 companies.
How many clinical trials target Breast Cancer?
There are 355 clinical trials targeting Breast Cancer tracked by BioSniper.
What is the prevalence of Breast Cancer?
The estimated prevalence of Breast Cancer is approximately 287.0 per 100,000 population.